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Abstract
COVID-19, the disease caused by the coronavirus SARS-CoV-2, has inflicted considerable suffering on
the human population. In this paper, we aim to significantly expand the resources available to biological
and clinical researchers who are developing therapeutic targets for drug development and repositioning.
Taking a genome-scale, systems-level view of virus-host interactions, we adapt and specialize network
label propagation methods to prioritize drug targets based on their probability to inhibit host-pathogen
interactions or their downstream signaling targets. In particular, our results suggest that we can predict
human proteins that interact with SARS-CoV-2 proteins with high accuracy. Moreover, the top-ranking
proteins scored by our methods are enriched in biological processes that are relevant to the virus. We
discuss cases where our methodology generates promising insights, including the potential role of HSPA5
in viral entry, the connection of HSPA5 and its interactors with anti-clotting drugs, and the role of
tubulin proteins involved in ciliary assembly that are targeted by anti-mitotic drugs. Several drugs that
we discuss are already undergoing clinical trials to test their efficacy against COVID-19. We make the
prioritized list of human proteins and drug targets broadly available as a general resource for repositioning
of existing and approved drugs as anti-COVID-19 agents or for novel drug development.
1 Introduction
The COVID-19 pandemic has created many clinical, economic, and societal challenges world-wide. It has
galvanized scientists to develop vaccines and drugs for the disease [1, 2]. Hundreds of drugs are already in
clinical trials that test their effectiveness against COVID-19. These drugs interfere with different aspects of
the viral life cycle, including fusion with the cell membrane, proteolysis, translation, and RNA replication.
Since a virus must necessarily co-opt host cellular processes in order to replicate, an alternative approach is to
develop or repurpose drugs that target human proteins that the virus requires. To this end, a global, whole-
genome view of host-pathogen interactions is likely to be valuable [3], especially in the case of SARS-CoV-2,
given the size of its genome and the complexity of the observed clinical and epidemiological manifestations
of COVID-19 [4].
In this work, we propose a drug repositioning strategy based on network-based functional label prediction
to prioritize existing, approved drugs as anti-COVID-19 agents (Figure 1). We base our approach on the
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Figure 1: Our analysis framework comprising of network propagation, selection of top-ranking proteins,
functional enrichment, and analysis of drugs.
hypothesis that human proteins belonging to complexes or signaling pathways that are proximal to viral
proteins are potentially good targets for inhibition. Accordingly, we take advantage of a recently published
dataset of human proteins that physically interact with SARS-CoV-2 [5]. This set is likely to have both
false positives and false negatives. For instance, the relative expression of the viral protein in the assay
may increase the number of interacting partners detected, generating false positives. In vivo conditions
and tissue-specific interactions may not be captured by this assay, producing false negatives. Therefore, to
prioritize additional human proteins, we formulate a network labeling problem: given the known human
protein interactors of SARS-CoV-2 proteins and a whole-genome protein interaction network, use network
diffusion algorithms to predict the other potential interactors with high accuracy. We further analyze highly-
ranking proteins computed by these methods to identify statistically-enriched biological cellular processes
and pathways that may be impacted by SARS-CoV-2. Additionally, we integrate drug-protein interactions
into this framework to pinpoint drugs that may be repositioned against COVID-19. We present two case
studies that illustrate how highly-ranked drugs, some of which are already in clinical trials for COVID-19,
may inhibit the virus in different stages of its life cycle. We stress that the drugs discussed in this work
are in silico predictions that require further experimental and clinical validation before they can be used as
treatments for COVID-19.
2 Results
We first present our results for cross-validation before discussing enrichment of GO terms. We conclude with
two case studies that highlight the ability of our methods to pinpoint drug targets and drugs that are likely
to be relevant to COVID-19.
2.1 Cross-Validation Performance
In order to prioritize putative human protein interactors of SARS-CoV-2 [5], we took inspiration from the
success of network propagation in diverse applications in systems biology [6]. We applied the Regularized
Laplacian (RL), a widely-used technique for network diffusion, GeneMania (GM) [7], a variant that have been
used for finding associations between GO terms and proteins, and SinkSource (SS) [8], a related approach used
to prioritize human proteins that are dependency factors for HIV. We also used two off-the-shelf classifiers:
Support Vector Machines with linear kernels (SVM) and Logistic Regression (LR), with the adjacency vector
of each human protein serving as its feature vector. Finally, we tested a method we call Local, which sets
each node’s score to be the weighted average of the scores of its neighbors.
We evaluated the performance of these algorithms using 5-fold cross validation of the 333 positive exam-
ples (human interactors of SARS-CoV-2 proteins). We used three measures of performance: the area under
the receiver-operator characteristic curve (AUROC), the area under the precision-recall curve (AUPRC), and
the precision at a recall of 0.1 (early precision). The third measure permitted us to estimate the accuracy
of the methods for high-confidence proteins, which are likely to be the basis for experimental validation.
For this computation, we needed negative examples. Since datasets of human proteins that are certain
not to interact with SARS-CoV-2 proteins are not available, we took the simple expedient of sampling them
2
RL GM SS SVM LogReg Local
0.5
0.6
0.7
0.8
0.9
1.0
A
U
P
R
C
RL GM SS SVM LogReg Local
0.5
0.6
0.7
0.8
0.9
1.0
A
U
R
O
C
RL GM SS SVM LogReg Local
0.5
0.6
0.7
0.8
0.9
1.0
E
a
rl
y
 P
re
ci
si
o
n
 @
0
.1
 R
e
ca
ll
(a) (b)
protein import into
mitochondrial matrix
NADH dehydrogenase
complex assembly
mitochondrial ATP synthesis
coupled proton transport
oligosaccharide-lipid intermediate
biosyntheticprocess
R
L
S
V
M K
r
cilium assembly
microtubule nucleation
protein transmembrane transport
intra-Golgi vesicle-mediated transport
Rab protein signal transduction
tRNA export from nucleus
mRNA transport
viral transcription
ribonucleoprotein complex biogenesis
cleavage involved in rRNA processing
ribosomal large subunit assembly
aerobic respiration
GPI anchor biosynthetic process
protein folding in ER
endoplasmic reticulum to cytosol transport
protein N-linked glycosylation via asparagine
protein alpha-1,2-demannosylation
zinc ion transport
Golgi organization
2
4
6
8
10
12
14
16
18
20
-l
o
g
(p
v
a
l)
regulation of response to ER stress
Figure 2: Network propagation results. (a) Comparison of AUPRC, AUROC, and precision at 0.1 recall
across six algorithms. The positive:negative ratio is one. The dashed line indicates the score for a random
predictor. ’LogReg’ is an abbreviation for logistic regression. (b) Heat map summarizing GO biological
process terms enriched in top ranking predictions from RL and SVM compared to human interactors of
SARS-CoV-2 proteins (indicated as ’Kr’).
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from the protein interaction network. We consider three different numbers of negative examples: as many
as, five times, and ten times the number of positive examples.
RL achieved a median AUROC of 0.76, a median AUPRC of 0.75, and an early precision of 0.89, values
which were approximately 1.5–1.8 times superior to those of a random predictor. SVM and logistic regression
achieved somewhat lower scores than RL. GM and SS performed slightly worse, except that GM had virtually
the same median early precision value as RL. The performance of Local (median AUPRC of 0.66, AUROC of
0.72, and early precision of 0.7) was much poorer than all the other methods, especially for early precision.
We obtained these results when we sampled as many negative examples as positive. When we increased the
sample size to five times or ten times the number of positives, RL continued to achieve the highest measures
of performance (Figure S2), with GM, SVM, and logistic regression achieving lower scores than RL. Local
continued to be the worst-performing method, which reinforced the power of network propagation in this
context.
This ability to accurately predict missing interactors of SARS-CoV-2 encouraged us to apply these meth-
ods to the entire human protein interaction network. To this end, we used the full set of positive examples
to rank the remaining proteins in the STRING network. For techniques that required negative examples,
we averaged the results over 100 random samples, with a positive:negative ratio of 1:5. To estimate the
statistical significance of the node scores, we adopted a null hypothesis corresponding to the scores gener-
ated by a random set of positive examples (of equal size to the true positive set). We note that the degree
distribution of the positive set has a strong impact on the scores received by a given protein; hence we took
care to approximately match the degree distribution of the random positive set and the true positive set,
via a stratified sampling approach (see Section 4.2 in “Methods”). To understand the diversity of the
predictions across these methods, between each pair of algorithms, we computed the Spearman’s correlation
of all scores. We also compared the top-ranking predictions between algorithms using the Jaccard index. RL
had a high correlation with Local (0.75), which was surprising given the poor performance of Local. How-
ever, the Jaccard index for the two methods was around 0.1 (Figure S1(b)), suggesting that the shared very
few top-ranking predictions and that the high correlation may be caused by lower-scoring proteins. SVM
had moderate values of correlation and Jaccard’s index with RL and SS (around 0.4 and 0.3, respectively).
Logistic regression and GM both had low correlations and Jaccard’s indices with all other methods (< 0.15).
Based on these observations, for subsequent analyses, we selected one network propagation method (RL)
and one supervised classifier (SVM). We preferred RL since it performed the best in our evaluations, especially
for early precision (Figure 2(a)). We chose SVM since it also had very good performance in cross-validation.
Moreover, the protein rankings computed by these methods were fairly dissimilar (Spearman’s correlation of
0.4 and Jaccard index of 0.3 for the top-300 ranks). We considered the top 332 predictions of RL and SVM
that were statistically significant at p ≤ 0.05 (Section 4.2), i.e., we selected as many top-ranking proteins as
the number of experimentally-determined human proteins that interact with SARS-CoV-2 proteins [5]. We
refer to these as “top-ranking proteins” below. We reasoned that due to their low overlap, using both sets
of proteins would result in broader coverage of human cellular processes and provide additional insights into
the potential effects of SARS-CoV-2 than using the results of just one method.
2.2 Enriched Biological Processes
We tested for enrichment of Gene Ontology (GO) biological processes (Benjamini-Hochberg corrected p-
value < 0.01) among the top-ranking proteins from RL and from SVM, as well as in the 332 interactors of
SARS-CoV-2 (“Methods”). Since parent-child relationships in the GO cause many closely related terms to
be enriched, we used a heuristic to select a non-redundant set of terms that were enriched in at least one of
these sets of proteins (“Methods”). While some terms were common to all three sets of proteins, there were
many that were enriched only in our predictions (Figure 2(b)), indicating that network propagation could
identify specific cellular processes that involved proteins that were proximal to but did not directly interact
with viral proteins. We examined the relevance of these processes to the viral cell cycle.
Several GO terms related to protein transport are enriched in top-ranking proteins from RL and SVM,
e.g., “protein transmembrane transport”, which has a p-value of 1.51×10−13 in RL and 0.009 in SARS-CoV-2
interactors. Many of these proteins are translocases of the inner and outer membranes of the mitochondrion.
These proteins comprise complexes that transport proteins across the mitochondrial membranes. They are
also known interactors of HIV proteins. In fact, almost 20% of the top-ranking proteins from RL also interact
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with HIV proteins, suggesting common host mechanisms that may be affected by both SARS-CoV-2 and
HIV.
The term “(GPI)-anchor biosynthetic process” is significantly enriched in the top-ranking results from
both RL and SVM (p-value 3.47 × 10−4 and 6.49 × 10−8, respectively) but not in the human interactors
of SARS-CoV-2 (p-value 0.18). The proteins prioritized by our methods are either components of the Gy-
cosylphosphatidylinositol (GPI-transamidase complex or transfer GPI to proteins during the synthesis of
GPI anchors; these anchors tether proteins to lipid bilayers [9]. GPI-anchored proteins are often associated
with lipid rafts, which are microdomains in plasma membranes that are enriched with cholesterol and sph-
ingolipids [9]. Lipid rafts play a major role role in viral entry, assembly, replication, and budding. They
are known to be involved in the entry of SARS-CoV into host cells [10]. Thus, the proteins (GPI)-anchor
biosynthesis that we prioritize may shed light on SARS-CoV-2 entry into host cells.
2.3 Case Study 1: HSPA5 and Anti-Clotting Drugs
GO biological process “Protein folding” was enriched in the top-ranking proteins (p-value 1.36 × 10−11 for
RL, 9.7×10−6 for SVM, and 3.42×10−4 for interactors of SARS-CoV-2). Viral protein NSP9 interacts with
several human nucleoporins (NUP54, NUP62, NUP88 and NUP214) [5], which in turn are connected to heat
shock proteins HSPA5 and HSPA13 in the STRING network (Figure 3(a)).
HSPA5, also referred to as glucose regulated protein (GRP78) or immunoglobulin binding protein (BiP)
in the literature, is evolutionarily conserved from prokaryotes to humans [11]. It has a repertoire of functions
associated with endoplasmic reticulum (ER) stress response. HSPA5 is usually localized in the ER. When
the ER is stressed, HSPA5 can translocate to the cell surface, the nucleus and mitochondria [12, 13]. On
the cell surface, HSPA5 plays a multi-functional role in cell proliferation, cell viability, ihibition of apoptosis,
and immunity [13, 14].
HSPA5 has been proposed as a universal target for human diseases [15]. It has increasingly well-
documented essential interactions and activities during viral infections. In particular, the role of HSPA5
in viral entry and pathogenesis has been widely investigated. As a cell surface protein, HSPA5 has been
reported to play an important role in viral entry [16, 17]. SARS-CoV infection has been shown to lead to
endoplasmic reticulum stress and the up-regulation of HSPA5 [16, 17]. The S protein of SARS-CoV can
cause transcriptional activation of HSPA5 [17]. The protein also augments the entry of MERS-COV into
permissive cells [18]. In the case of bat coronavirus (bCOV HKU9) it was shown to serve as a point of
attachment [18]. Both Zika virus and Japanese encephalitis virus use HSPA5 as a co-receptor, to prevent
apoptosis, and to help in viral replication [19]. Recently, HSPA5 has been identified as a potential receptor
for SARS CoV2 [20]. It has also been identified as a receptor for SARS CoV2 in airway epithelial cells [21].
Based on these recent reports, we hypothesize that HSPA5 may serve as a co-receptor, a point of viral
attachment, or aid in viral entry of SARS-CoV-2.
Blood hypercoagulability is reported to be common among COVID-19 patients [22]. We now turn our
attention to the linkage between the “protein folding” network (Figure 3(a)) and coagulation and suggest
how anti-coagulant drugs may act within the context of COVID-19. SARS-CoV-2 protein Orf8 interacts with
human hypoxia up-regulated protein 1 (HYOU1). HYOU1 (also known as GRP170) plays a cytoprotective
role in response to oxygen deprivation[11]. Apart from HSPA5, HYOU1 interacts with calnexin (CALX) and
calreticulin (CALR), both of which are chaperone proteins found in the endoplasmic reticulum [23]. HSPA5,
CALX and CALR act as protein chaperones for pro-coagulant proteins such as Factor V and Factor VIII.
Once Factor VIII is secreted, it binds to another pro-coagulant protein von Willebrand factor (vWF) to
prevent degradation of clots [24]. Although Factor V, Factor VIII, and vWF are not among the top-ranking
proteins and thus do not appear in Figure 3(a), this network is suggestive of mechanisms that SARS-CoV-2
may use to cause abnormal blood coagulation.
Anti-coagulant drugs that interact with HSPA5, CALX or CALR include Tenecteplase, a third generation
plasminogen activating enzyme and the investigational drug Lanoteplase, which is a serine protease that binds
to fibrin leading to the formation of plasmin [25], an enzyme that breaks clots. Lanoteplase is a second-
generation derivative of alteplase, and a third generation derivative of recombinant plasminogen. It is notable
that there is a clinical trial for Alteplase (NCT04357730) to test its effectiveness for COVID-19. Calcium
citrate, a known anti-coagulant agent also interacts with CANX and CALR [26]. Aspirin, also present in
(Figure 3(a)), binds to and inhibits the ATPase activity of HSPA5 [27]. Clinical trial NCT04363840 is testing
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Figure 3: Network of the top-ranking proteins for RL (green nodes) that are annotated to the enriched terms
(a) “protein folding in endoplasmic reticulum” or (b) “cilium assembly.” A yellow rectangle encompasses
proteins annotated to the respective term. We removed STRING edges with an edge weight < 900 to simplify
the visualization. Proteins discussed in the text are highlighted with a red border. We also included the
paths to the closest viral proteins (red diamonds) from each of the top ranking proteins. In a, we limited
drugs to those that are anti-clotting. In b, we limited proteins to those that are the target of an approved
or investigational drug.
whether early treatment of COVID-19 patients with aspirin and vitamin D can inhibit the production of
blood clots and decrease rates of hospitalization.
2.4 Case Study 2: Tubulin-Modulating Drugs
Several GO biological processes related to cilia were significantly enriched in the top-300 RL and SVM
predictions (e.g., “cilium assembly,” GO:0060271, p-value 1.35×10−50 for RL and 6.53×10−59 for SVM but
not in the human interactors of SARS-CoV-2 (p-value 0.28). Many proteins annotated to this term belong
to the tubulin family, which are constituents of microtubules. The SARS-CoV-2 M protein binds to two
γ-tubulins (TUBGCP2 and TUBGCP3), which interact with several α- and β-tubulins among the top 300
predictions Figure 3(b)). Microtubules are polymers that provide shape and structure to eukaryotic cells
and are necessary in cell transport and cell division, among other functions [28]. α- and β-tubulins compose
microtubule filaments, while γ-tubulins connect them to the microtubule organizing center.
Viruses commonly utilize microtubules for cellular entry, intra-cellular trafficking, and exit from cells. For
instance, the Spike protein of humam α-coronavirus interacts with tubulin α and β chains [29], suggesting that
tubulin may be involved in the transport and localization of the S protein and its assembly into virions [29].
Relevant to SARS-CoV-2, microtubules are the primary structural component of cilia, which line epithelial
cells of the respiratory tract and are responsible for the transport of mucus out of cells [30]. The ACE2
receptor that SARS-CoV-2 uses to enter cells appears to be expressed primarily on the cilia of respiratory
tract epithelial cells [31, 32], further implicating microtubules in how the virus infects these cells. The
combination of high levels of ACE2 expression and presence of cilia may also explain the detection of the
virus in multiple organs [33] and the deleterious effect of COVID-19 on the renal, gastroinstestinal, and
olfactory systems [34].
Next, we turned our attention to drugs that targeted Tubulin proteins (Figure 3(b)). Our methods
prioritized the drug Colchicine (Figure 3(b)) since it had the smallest p-value (0.001) among the approved
or investigational drugs that target proteins annotated to “ciliary assembly.” Colchicine is FDA-approved
for treating gout. Its effectiveness against COVID-19 is being tested in four ongoing clinical trials, among
those listed on clinicaltrials.gov.
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The drugs that target proteins involved in ciliary assembly (Figure 3) are mostly anti-mitotic agents,
which are also being tested as anti-cancer therapeutics. These drugs fall into three broad classes depending
on how they affect the dynamic equilibrium between free and polymerized tubulin [35]. Colchicine, Podofilox,
Vinchristine, Vinflunine, and Vinblastine destabilize microtubules by binding to specific sites of α- and β-
tubulins, thereby preventing their assembly. Albendazole, Mebendazole, and Oxibendazole, Cabazitaxel,
Milataxel, and CYT99 (a synthetic drug) inhibit tubulin polymerization thereby affecting the assembly
and dynamics of microtubules and slowing cell growth. Two other drugs in this network, Patupilone and
Epithilone-D, also cause cell-cycle arrest but by a different mechanism: they stabilize the tubulin network. In
the case of COVID-19, we hypothesize that drugs that destabilize the microtubule network might prove to be
more efficacious since they may prevent viral proteins from using microtubules for intra-cellular trafficking. In
addition, as in the case of Colchicine, they may act as anti-inflammatory agents and may provide additional
benefits to COVID-19 patients.
3 Discussion
Drug development is widely acknowledged to be one of the most challenging industrial processes requiring
billions of dollars and high levels of diverse expertise to overcome profound scientific and logistic barriers.
There remains a high failure rate in the steps that lie between discovering a drug target and manufacturing
a drug for market. As a result, multiple diseases ranging from a “simple” flu caused by the Influenza virus
to more complex conditions such as Type 1 Diabetes and Alzheimer’s disease have no effective drugs. HIV
research has produced an effective combination therapy, but it took years to develop despite unprecedented
world-wide investment. The COVID-19 pandemic and its medical and economic impact created a new and
urgent challenge for the research and pharmaceutical communities to develop a therapeutic response. As
one manifestation of this community response, a recent transformative proteomics effort by a consortium
of scientists generated a first-of-a-kind interactome associated with the SARS-CoV-2-human interface [5].
This interactome inspired a large-scale drug repositioning effort targeting the human proteins that directly
interact with the virus.
This important and timely advance is only the beginning of a very promising direction in drug devel-
opment for COVID-19. The set of human proteins reported to interact with SARS-CoV-2 is likely to have
both false positives and false negatives due to the properties of the proteomic screening pipeline used. Thus,
we sought to further the results of this study and significantly expand the resource available to the drug
development and drug repositioning community through the use of state-of-the-art network prediction algo-
rithms. We also hoped to demonstrate that the area of function prediction using network propagation has
achieved significant technological maturity since its introduction over 15 years ago [36, 37, 38, 39]. In partic-
ular, network diffusion style approaches to implement label propagation have evolved to be relatively easy
to implement and validate statistically [6], thereby making them amenable for translational research. The
CAFA benchmarking efforts have been helpful to identify the best performing protein function prediction
methods as well [40].
In this paper, we take full advantage of these mature predictive platforms to significantly expand the
resources available to the COVID-19 community by producing a larger set of putative SARS-CoV-2 inter-
actors. Many of these proteins could serve as drug targets and several are already under development or in
clinical trials. Our prediction methods predict interactors with high accuracy. We expect this performance
to be further improved by the computational biology community building on our and other resources.
Our initial findings suggest old as well as new drug targets. Several targets are associated with ER stress,
a well-documented initial response to viral infections with lethal or severe clinical outcomes. These ER stress
response proteins include a number of well-studied heat shock proteins (HSPA9, rank 9, p-value 0.03 and
HSPA5, rank 18, p-value 0.018 for RL). We have discussed one of them, HSP5A, as a promising drug target.
However, other HSPs in our prediction list are also natural targets for drug repositioning. More broadly,
targeting ER stress is a promising direction to reduce ROS associated cell death [41].
We also considered transcription factors (TFs) as a regulatory signature of putative SARS-CoV-2 in-
teractors. The targets of a number of very well-known TFS are enriched among our top-ranking proteins.
These TFs include well-known regulators of the cell cycle (ATF) and cellular differentiation (MEF2). One
TF that stands out is SREBP1, which is associated with hormonal regulation and liver function. A number
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of COVID-19 patients with severe outcomes have demonstrated abnormal liver enzyme function [42]. The
link to SREBP1 may suggest a new direction to examine liver-associated outcomes of SARS-CoV-2 infection.
This direction must be critically evaluated further, e.g., by integration with gene expression studies, and was
not pursued in this work.
In addition to the primary drug targets we have identified in “Results”, we point out VDAC proteins,
which are voltage-dependent anion channels (e.g., VDAC2, rank 99, p-value 0.042 and VDAC1, rank 182,
p-value 0.034 for RL) ) that have been associated with mitochondria-triggered pro-apoptotic processes.
Several recently identified inhibitors of VDAC1 may be speculatively considered as potential therapeutic
interventions to inhibit anion transport channels. An example is DIDS, which leads to a potential decrease
in ROS associated cell death [43].
Further, a number of dehydrogenases appear among our top ranking proteins (GO biological process
“NADH dehydrogenase complex assembly” has a p-value of 2.7 × 10−12 for RL in contrast to a p-value of
0.035 in SARS-CoV-2 interactors). NADH dehydrogenases are also shared between human interactors of
HIV and SARS-CoV-2. This finding naturally promotes NADH as a promising drug target to treat infection-
associated ER stress. NADH is also associated with metabolic health and has been studied as an energy
currency, suggesting a number of promising biological follow-ups. Viral infections have been proposed to
cause the so-called Warburg effect that is frequently associated with cancer [44]. Due to oxygen deprivation,
cells switch from respiration to glycolysis. This Warburg effect is targeted by a number of metabolic drugs,
which offer new directions for viral treatments with these small molecules. Oxidative phosphorylation has
also been documented in Type 2 Diabetes as an important corollary of metabolic disease [45, 46]. We also
note the classical connection between elevated inflammation and metabolic slowdown associated with both
aging and viral infections [47]. Thus, a combined immuno-metabolic combinatorial drug regimen might be
worth considering for COVID-19 patients to prevent severe outcomes.
We have already begun to integrate our current techniques both with other omics data and with or-
thogonal methods that increase the chances for biologically meaningful predictions. In particular, single-cell
RNAseq data offer many opportunities to examine cellular heterogeneity and context-specific interactions.
In this context, we note complementary efforts to repurpose drugs for SARS-CoV-2 that are based on pro-
tein structures [48], observational studies of treatments being administered to patients [49], and shortest
paths [50].
In summary, this paper provides a significantly expanded resource for drug repurposing and development
to the COVID-19 community. The relatively quick turn-around of this project and the host-virus protein
interaction resource on which we have built [5], demonstrates that biological network science and network
propagation [6] have achieved significant maturity. These efficient computational methods and rapidly gen-
erated data allow us to develop high accuracy predictions of enzymes involved in specific functional activities
as an expeditious response to newly emerging diseases, in addition to the already strong presence of these
methods in cancer and chronic diseases.
4 Methods
4.1 Algorithms
We describe each of the algorithms we use for label propagation and prediction. We are given a weighted,
undirected network G = (V,E,w) and a set P of positive examples, which in our case is the set of human
proteins that interact with SARS-CoV-2 proteins [5]. We seek to compute a score s(v) ≥ 0 for every node
in G that indicates our confidence that v is an interactor of SARS-CoV-2 proteins.
Regularized Laplacian (RL) [51]. This method defines a label vector ~y over the nodes in G where
y(u) = 1 if node u is a SARS-CoV-2 interactor and y(u) = 0, otherwise. It computes a score s(u) between 0
and 1 for each protein u in G. Let W ∈ Rn×n denote the adjacency matrix of G and W˜ = D−1/2WD−1/2
denote the normalized network, where D is a diagonal matrix with Duu =
∑
v auv, for every node u in G.
Then, to compute the scores for each node, we minimize the following sum, where α > 0 is a parameter:∑
u∈V
(
s(u)− y(u))2 + α ∑
(u,v)∈E
w˜uv
(
s(u)− s(v))2,
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where n is the number of nodes in the graph and the minimization ranges over all vectors s ∈ Rn. We note
that L˜ = I − W˜ is the normalized Laplacian of G. To minimize the above expression, we solve the system
of linear equations (I + αL˜)~s = ~y. It can be shown that for any connected graph G this system always has
a unique solution, and that (I + αL˜) is always invertible. The matrix (I + αL˜)−1 can be interpreted as the
amount of diffusion that flows in the network between any two node pairs, and is termed the Regularized
Laplacian [51].
GeneMANIA [7]. This method is a variation of RL that can take negative examples into consideration.
Starting with a label vector ~y where y(u) represents the prior evidence for protein u being a SARS-CoV-2
interactor, this algorithm computes a score s(u) between −1 and 1 for each protein u in G. The value of
y(u) is 1 or -1 if u is a positive or negative example, respectively. Let the number of positive examples be n+
and the number of negative example be n−. If u is an unknown example, then y(u) = n
+−n−
n++n− , the mean of
the labels of the labeled nodes. Apart from this definition of ~y, this method is identical to RL. Note that the
original version of GeneMANIA implicitly chose α = 1. We introduce the parameter α to allow a tradeoff in
the importance given to the input node labels ~y vis-a-vis the similarity of adjacent labels in the output ~s.
SinkSource [8]. This method fixes the score s(u) = 1 for every positive example and s(u) = −1 for every
negative example. It computes the score of every other node in G by minimizing the following function:∑
(u,v)∈E
wuv
(
s(u)− s(v))2.
Let U denote the set of nodes in G that are unlabeled, i.e., are not positive or negative examples. For every
node u ∈ U , we define the set of its neighbours as N(u) and use
f(u) =
∑
v∈N(u)
v is positive
wuv −
∑
v∈N(u)
v is negative
wuv
to denote the sum of the weighted scores of its neighbors that are positive or negative examples. Let ~f denote
the vector containing these values and let W denote the adjacency matrix of the subgraph of G induced by
U . Defining D as a diagonal matrix of W as in the case of GeneMANIA but only for the nodes in U , we
compute ~s as the solution of the linear system of equations (I +WD−1)s = f .
When negative examples are not available, as is the case here, SinkSource adds an artificial negative
example to the network, and connects each node to the artificial negative with an edge of weight λ, where
λ > 0 is a tunable parameter.
Local. We set s(v) = 1 for every node in P . For every other node u, we initialise s(u) = 0 and then
compute s(u) as the weighted average of the scores of its neighbors.
Support Vector Machine (SVM). We set each node’s feature vector to be its adjacency vector in the
normalized network W˜ . We trained a linear kernel using the LinearSVC function in the scikit-learn
Python package with default parameters.
Logistic Regression. We set each node’s feature vector as in the case of SVM. We used the
LogisticRegression function in the scikit-learn Python package with default parameters.
4.2 Statistical Significance
To estimate the statistical significance of each node’s scores, we adopted a null hypothesis corresponding
to the distribution of scores obtained from a randomly chosen positive set P ′ where |P ′| = |P |. (As an
alternative to randomizing the positive set, randomizing the network (e.g., via a degree-preserving edge swap
process) would destroy the correlations between adjacent nodes (homophily) that are important contributions
to pathway and neighborhood structure in the network.) We note that the degrees of the nodes in P may
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have a strong effect on the resulting distribution of scores. For example, if many nodes in P have high
degree, then scores may tend to be larger overall than if there are few nodes in P with high degree. Thus if
the degree distribution of P does not approximately match that of P ′, the resulting p-values will be biased.
Had we selected each random sample uniformly at random from all nodes in G, then the degree distribu-
tion of the chosen nodes would not be ensured to match that of the nodes in P . Therefore, we implemented
a stratified sampling approach, as follows: Given a number of bins b, we partitioned the nodes in G into b
sets using one of two techniques:
1. We sorted the nodes by weighted degree, i.e., we computed the degree sequence of G. We partitioned
this sequence into b equal-sized groups.
2. We executed k-means clustering on the degree sequence of G to compute b clusters (ie, we set k = b in
the k-means algorithm).
The first approach emphasizes nearly-equal-sized groups, while the second approach emphasizes nearly-equal-
degree groups. Then, to generate a random sample P ′ having |P | nodes, for every positive example v in P ,
we determined the subset whose range endpoints contained v and sampled a node from that subset uniformly
at random. After evaluating various values of b, we selected the second approach and b = 10 for use in our
results (see Appendix S2.1 for details).
For each P ′ we designated these nodes to be the set of positive examples and executed each of the
prediction algorithms, ensuring that the negative samples we selected for each P ′ did not intersect with the
original set of positive examples P . Repeating this procedure 1,000 times, we constructed a distribution of
scores for each node in P . We then estimated the p-value of a node’s score as the fraction of values in this
distribution that were at least as large as the score. We did not correct these scores for multiple hypothesis
testing.
4.3 Datasets
SARS-CoV-2 - Human PPIs. We obtained 332 human proteins that interact with SARS-CoV-2 [5] and
treated them as positive examples for our analysis. We added the ACE2 receptor to this set.
Functional and protein interaction networks. We started with the human functional interaction
network in the STRING database (version 11) [52], comprising of 18,886 nodes and 977,789 edges after
applying a “medium” score cutoff of 400. We used the interaction reliabilities provided by STRING as edge
weights; we divided each value in STRING by 1, 000 to scale them between 0 and 1.
Negative Examples. To evaluate the precision of our predictions, we artificially created negative examples
by sampling them uniformly at random from the STRING network. We selected 1, 5, and 10 times as many
negative examples as positives.
Drug-protein interactions. We downloaded interactions among drugs and proteins from the DrugBank
database (version 5.1.6) [53]. This dataset contained 16,503 drug-protein target pairs among 5,665 drugs
and 2,891 target proteins. Limiting the targets to those in the STRING network reduced the number of
drugs and targets to 5,589 and 2,769, respectively.
4.4 Evaluation
We evaluated the prediction algorithms using 100 runs of five-fold cross validation. In each run we ensured
that all algorithms saw identical partitions of the examples into folds. We computed three measures of
performance: (a) the area under the receiver operator characteristic (ROC) cruve. (b) the area under the
precision-recall curve, and (c) precision at a recall of 0.1 (early precision).
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4.5 Function Enrichment
We used the clusterProfiler package in R [54] to compute Gene Ontology terms, KEGG pathways, and
Reactome pathways enriched in our predictions or in the human interactors of SARS-CoV-2 proteins. This
package uses Fisher’s exact test to estimate the enrichment of an individual term or pathway and the method
of Benjamini and Hochberg to correct for testing multiple hypotheses. We applied this correction for each
database (GO, KEGG, Reactome) separately. We used a threshold of 0.01 to decide if a GO term or
KEGG/Reactome pathway was significantly enriched.
The enrichment analysis yields many highly similar statistically significant GO terms and KEGG and
Reactome pathways; by “similar”, we mean that two different terms or pathways may annotate many proteins
in common. This problem is well-known with several approaches that have been proposed to mitigate it either
by grouping similar terms and selecting a small subset of dissimilar terms [55, 56] or by directly computing
a set of non-redundant GO terms [57, 58]. As far as we can tell, these methods have been developed to
consider the enriched GO terms for one set of terms. When we apply them independently to different sets
of proteins (e.g., predictions from RL and predictions from SVM), they may select one term for one set of
proteins but a similar but not identical term for another set, making the distinctions in enrichment hard to
discern.
Therefore, taking inspiration from previously developed methods (cited above), we developed a simple
heuristic based on the weighted set cover algorithm that simultaneously simplifies multiple sets of enriched
terms or pathways. For every term that is enriched in at least one protein set, we defined its composite
odds ratio to be the product of the odds ratios for that term across the protein sets. We iteratively selected
the term with the largest composite odds ratio, adjusted the odds ratio for every term by subtracting the
proteins annotated to the selected term, and recomputed the composite odds ratio. We stopped when every
annotated protein was covered by at least one selected term.
For each of a small number of terms automatically selected by this algorithm, there was a different, highly
overlapping term that we felt would be more interpretable in the context of SARS-CoV-2 and COVID-19,
e.g., “cilium assembly” instead of “ciliary basal body-plasma membrane docking.” Therefore, we manually
replaced the selected terms by their alternative choices. In addition, we manually removed a few terms with
a small number of annotations (≤ 7) that were similar to other terms in the simplified list. We used the
final list of terms for further analysis.
5 Data and Software Availability
Our software is available under the GNU Public License version 3 at https://github.com/Murali-group/
SARS-CoV-2-network-analysis.
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Supplementary Table 1: The prediction rank and p-value computed by RL and SVM for each human
protein on the STRING network, the list of drugs that target the protein (when this information is
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available in DrugBank), and the closest SARS-CoV-2 interactor and SARS-CoV-2 protein. For the
last piece of information, we computed the shortest weighted path, where we defined the weight of a
path to be the sum of the absolute value of the base-10 logarithm of the weights of the edges in the
path.
Supplementary Table 2: Table of enrichment results for RL, SVM and the viral interactors on GO bio-
logical processes.
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Figure S1: Similarity of predictions between every pair of methods. (a) Spearman correlations of node
prediction scores. (b) Overlap of the top k predictions of each method, measured using the Jaccard index.
The number in each cell is the value of the corresponding correlation or Jaccard index multiplied by 100.
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Figure S2: Cross validation results for positive:negative ratios of 1:5 and 1:10.
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S2 Supplementary Text
S2.1 Parameter Selection
Algorithms. To tune the methods, we varied the diffusion strength parameter α for RL, the weight of
the edges λ connecting each node to the artificial sink for SS, and the parameter C controlling the inverse
of the regularization strength for SVM and LR. For each setting of these parameters, we repeated 5-fold
cross-validation with all three positive:negative ratios. We show the results for a ratio of 1:5 in Figure 1; the
results for the other ratios were very consistent. We focused on optimizing early precision values since we
were interested in the analysis of top-ranking predictions.
For RL, GM, and SS, we found that in general, constraining the propagation locally around positive
examples (i.e., small values of α, large λ) achieved higher early precision than more global propagation (i.e.,
large α, small λ). We chose the parameter values α = 0.01, α = 0.1, and lambda = 100 for RL, GM, and SS,
respectively.
For the supervised classifiers SVM and LR, we found that decreasing the regularization string (i.e., large
values of C) resulted in a slight increase in median early precision (about 0.05 for SVM, and 0.07 for LR)
over the default C = 1. However, to avoid overfitting, we chose to use C = 1 for both methods.
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Figure S3: Parameter search results for each method, evaluated using AUROC, AUPRC, and early precision
(at recall equal to 0.1) of 5-fold CV with a positive:negative ratio of 1:5 on the STRING network. Each
point shows the median value of 100 repetitions, with error bars showing the 95% confidence interval of the
median, estimated using 1,000 bootstrapped samples of the data.
Stratified sampling. The number b of bins is a parameter. We tested b = 10, 20, 30 and found that in
each case, almost all of the top 332 nodes had a p-value < 0.05 with the exception of the top 15 predictions
for SVM, many of which had p-values slightly higher than the cutoff (Figure S4). In general, the p-values
for SVM were slightly higher than those for RL. Since we did not observe much difference when varying b,
we selected b = 10.
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Figure S4: Base-10 logarithms of the p-values of node scores of the top 500 ranked proteins for RL and SVM
for three values of b. The red dashed lines show the significance cutoff of 0.05, while the diagonal line shows
x = y.
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